The role of miRNA in IBS pathogenesis, diagnosis and therapy: The latest thought DOI
Xiaoyu Zhang, Lei Shi, Chen Chen

et al.

Digestive and Liver Disease, Journal Year: 2024, Volume and Issue: 56(9), P. 1433 - 1441

Published: Feb. 10, 2024

Language: Английский

Bile acid diarrhea in patients with chronic diarrhea. Current appraisal and recommendations for clinical practice DOI Creative Commons
Giovanni Barbara, Massimo Bellini, Piero Portincasa

et al.

Digestive and Liver Disease, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Bile Acid Diarrhea (BAD) is a common cause of chronic diarrhea, often accompanied by urgency, occasional fecal incontinence, abdominal pain, and fatigue. A nationwide survey has shown limited awareness BAD within the Italian medical community, prompting panel experts to develop Position Paper that outlines most practical cost-saving diagnostic investigations treatments for this frequently overlooked condition. The document provides an overview epidemiology, pathophysiology, clinical manifestations, classification different types (BAD). key focus approach identifying managing many undiagnosed patients in both primary care specialized settings. Finally, paper addresses optimal therapeutic strategies BAD, including traditional bile acid sequestrants newer, promising treatments.

Language: Английский

Citations

1
Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis DOI Open Access

Xuan Ju,

Zhenliang Jiang,

Jiayin Ma

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(11), P. 1727 - 1727

Published: May 31, 2024

Context: Short-chain fatty acids (SCFAs) have been reported to be associated with the pathogenesis of irritable bowel syndrome (IBS), but results are conflicting. Objective: Here, a systematic review case–control studies detecting fecal SCFAs in IBS patients compared healthy controls (HCs) and self-controlled or randomized controlled trials (RCTs) investigating SCFA alterations after interventions were identified from several databases. Data sources: A search databases (PubMed, Web Science, Embase) 21 published before 24 February 2023. extractions: Three independent reviewers completed relevant data extraction. analysis: It was found that propionate concentration significantly higher than HCs, while acetate proportion lower. Low-FODMAP diets reduced microbiota transplantation probiotic administration did not change proportion. Conclusions: The suggested could used as biomarkers for diagnosis. low-FODMAP diet intervention potentially serve treatment FMT need more robust trials.

Language: Английский

Citations

6
The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome DOI Open Access
Vlad Ionescu, Gina Gheorghe,

Teodor Florin Georgescu

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(17), P. 5124 - 5124

Published: Aug. 29, 2024

Globally, irritable bowel syndrome (IBS) is present in approximately 10% of the population. While this condition does not pose a risk complications, it has substantial impact on patient’s quality life. Moreover, disease significant financial healthcare systems. This includes direct costs associated with diagnosis and treatment these patients, as well indirect that arise from work absenteeism reduced productivity. In light data, recent research focused elucidating pathophysiological basis order to improve life for affected individuals. Despite extensive date, we still do fully understand precise mechanisms underlying IBS. Numerous studies have demonstrated involvement gut–brain axis, visceral hypersensitivity, gastrointestinal dysmotility, gut microbiota dysbiosis, food allergies intolerances, low-grade mucosal inflammation, genetic factors, psychosocial factors. The acquisition new data crucial advancement optimal therapeutic approaches aimed at enhancing general health patients while simultaneously reducing burden ailment.

Language: Английский

Citations

5
The Neutrophil-to-Albumin Ratio (NAR): A Novel Index in Relation to Clinical Symptoms, Quality of Life, and Psychological Status in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) DOI Creative Commons

Xijing Huang,

An Li,

Ping Long

et al.

Journal of Inflammation Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 3685 - 3695

Published: June 1, 2024

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by chronic abdominal pain and alterations in habits. Despite the importance of biomarkers disease management, quest for precise non-invasive IBS continues.

Language: Английский

Citations

4
Mucoprotectants and gut barrier: mechanisms of action and clinical applications in IBS. Is there a possible role? DOI Creative Commons
Francesco Rettura, Christian Lambiase,

R. Tedeschi

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 12, 2025

Impaired gut barrier function plays a pivotal role in the pathophysiology of irritable bowel syndrome (IBS), particularly IBS with diarrhea. Mucoprotectants, such as xyloglucan, gelatin tannate and pea protein tannins, offer novel therapeutic approach by restoring intestinal permeability reducing inflammation. This review assesses preclinical clinical evidence supporting mucoprotectants diarrhea management. Preclinical studies indicate their efficacy inflammation, while trials demonstrate improvements stool consistency, abdominal pain bloating. Despite these promising results, comparative are needed to establish superiority specific optimal use practice.

Language: Английский

Citations

0
Microscopic Colitis: An Underestimated Disease of Growing Importance DOI Open Access

Kamil Rutkowski,

Karina Udrycka,

Barbara Włodarczyk

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(19), P. 5683 - 5683

Published: Sept. 24, 2024

The aim of this paper is to raise awareness MC as a clinically significant condition and highlight its under-recognition, risk factors, diagnosis, management, complications. This underlines the diagnostic therapeutic challenges associated with often nonspecific symptoms MC. In order create article, we reviewed available articles found in PubMed database searched for using Google Scholar platform. Microscopic colitis (MC) chronic inflammatory bowel disease, classified into three types: lymphocytic, collagenous, unspecified. average age onset around 62–65 years disease more common women than men (nine times common). main symptom watery diarrhoea without blood, other include defecatory urgency, faecal incontinence, abdominal pain, nocturnal movements, weight loss. Once considered rare now being diagnosed increasing frequency, but diagnosis remains difficult. To date, number causative factors have been identified, including smoking, alcohol consumption, medications (including NSAIDs, PPIs, SSRIs, ICPIs), genetic autoimmune diseases, bile acid malabsorption, obesity, appendicitis, intestinal dysbiosis. It may be difficult recognize should differentiated from diseases (Crohn’s ulcerative colitis), irritable syndrome (IBS), coeliac infectious others. Diagnosis involves biopsy at colonoscopy histopathological evaluation samples. Treatment consists budesonide oral (the gold standard) or enema. Alternatives sequestrants (cholestyramine, colesevelam, colestipol), biologics (infliximab, adalimumab, vedolizumab), thiopurines, methotrexate, rarely, surgery.

Language: Английский

Citations

1
The impact of lactose intolerance diagnosis: costs, timing, and quality-of-life DOI

Simona Dominici,

Nico Donati,

Sofia Menabue

et al.

Internal and Emergency Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 4, 2024

Language: Английский

Citations

1
Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes? DOI Creative Commons
Gabrio Bassotti

Expert Opinion on Investigational Drugs, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 4

Published: April 24, 2024

Language: Английский

Citations

0
The role of miRNA in IBS pathogenesis, diagnosis and therapy: The latest thought DOI
Xiaoyu Zhang, Lei Shi, Chen Chen

et al.

Digestive and Liver Disease, Journal Year: 2024, Volume and Issue: 56(9), P. 1433 - 1441

Published: Feb. 10, 2024

Language: Английский

Citations

0